CHARLOTTESVILLE, VA – December 21, 2007 – Diffusion Pharmaceuticals LLC, a clinical stage drug-development company commercializing first-in-class drugs utilizing a novel mechanism of action that enhances oxygen diffusion, today announced that one of its key advisors, Mr. Thomas Byrne, was recently recognized as a co-inventor of the underlying technology of Amgen’s blockbuster drug Aranesp® (darbepoietin [...]

CHARLOTTESVILLE, VA – September 28, 2007 – Diffusion Pharmaceuticals LLC, a clinical-stage drug development company commercializing first-in-class drugs utilizing a novel mechanism of action that enhances oxygen diffusion, today announced the results of a Phase I safety trial of its lead drug candidate, trans sodium crocetinate (TSC). In addition, the company announced the completion of [...]

CHARLOTTESVILLE, VA – April 26, 2007 – Diffusion Pharmaceuticals LLC, a clinical-stage drug discovery and development company pioneering a revolutionary approach to the treatment of life-threatening diseases, today announced that it has formed a Scientific Advisory Board (SAB) to advise the Company on its clinical development programs. The SAB, comprised of four noted scientists and [...]

CHARLOTTESVILLE, VA – March 16, 2007 – Diffusion Pharmaceuticals LLC, a clinical-stage drug discovery and development company, today announced the initiation of human testing of trans sodium crocetinate (TSC), its lead drug candidate. TSC, which uses a novel mechanism of action to enhance the diffusion of oxygen into tissue, is being studied as a potential [...]

CHARLOTTESVILLE, VA – February 2, 2007 – Diffusion Pharmaceuticals LLC, a drug discovery and development company pioneering a revolutionary approach to treat life-threatening diseases, today announced that it has received a $0.5 million grant (N00014-07-C-0424) from the Office of Naval Research (ONR). The funds will be used to support the transition of the company’s lead [...]